appendix 1: eq-5d-3l descriptive system - springer978-94-007-5158-3/1.pdf · appendix 1: eq-5d-3l...
TRANSCRIPT
Appendix 1: EQ-5D-3L Descriptive System
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g., work, study, housework,family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
R. Brooks, The EuroQol Group after 25 years, DOI 10.1007/978-94-007-5158-3,# Springer Science+Business Media Dordrecht 2013
249
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
250 Appendix 1: EQ-5D-3L Descriptive System
Appendix 2: EQ-5D-5L Descriptive System
Mobility
I have no problems in walking about
I have slight problems in walking about
I have moderate problems in walking about
I have severe problems in walking about
I am unable to walk about
Self-care
I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g., work, study, housework,family or leisure activities)
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
251
Pain/Discomfort
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
252 Appendix 2: EQ-5D-5L Descriptive System
Appendix 3: EQ-5D-3L Official Language
Versions
253
Afrikaans (South Africa)
Arabic (Algeria, Jordan, Kuwait, Saudi Arabia, Tunisia, UAE)
Bangla (Bangladesh)
Bengali (India)
Bulgarian (Bulgaria)
Catalan (Spain)
Chinese (Simplified) (China, Malaysia, Singapore)
Chinese (Traditional) (Hong Kong, Taiwan)
Croatian (Croatia)
Czech (Czech republic)
Danish (Denmark)
Dutch (Belgium, the Netherlands)
English (Australia, Canada, Hong Kong, India, Malaysia, Malta, New Zealand, Philippines, UK
(also validated for Ireland), Singapore, South Africa, USA)
Estonian (Estonia)
Finnish (Finland)
French (Algeria, Belgium, France, Canada, Switzerland, Tunisia)
Georgian (Georgia)
German (Germany, Austria, Switzerland)
Greek (Greece)
Gujarati (India)
Hebrew (Israel)
Hindi (India)
Hungarian (Hungary)
Icelandic (Iceland)
Indonesian (Indonesia)
Italian (Italy)
Japanese (Japan)
Kannada (India)
Latvian (Latvia)
Lithuanian (Lithuania)
Malay (Malaysia)
(continued)
(continued)
Malayalam (India)
Maltese (Malta)
Maori (New Zealand)
Marathi (India)
Norwegian (Norway)
Polish (Poland)
Portuguese (Brazil, Portugal)
Punjabi (India)
Romanian (Romania)
Russian (Israel, Latvia, Russia, Ukraine)
Serbian (Serbia)
Slovak (Slovakia)
Slovenian (Slovenia)
Spanish (Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala,
Mexico, Panama, Peru, Puerto Rico, Spain, Uruguay, USA, Venezuela
Swedish (Finland, Sweden)
Tamil (India)
Telugu (India)
Thai (Thailand)
Turkish (Turkey)
Ukrainian (Ukraine)
Urdu (India, Pakistan)
Vietnamese (Vietnam)
Zulu (South Africa)
Latest update: April 2012
254 Appendix 3: EQ-5D-3L Official Language Versions
Appendix 4: EQ-5D-5L Language Versions
255
Afrikaans (South Africa)
Arabic (Israel)
Bengali (India)
Cebuano (Philippines)
Chinese (Simplified) (China, Malaysia, Singapore)
Chinese (Traditional) (Taiwan)
Czech (Czech Republic)
Danish (Denmark)
Dutch (Belgium, the Netherlands)
English (Australia, Canada, India, Malaysia, New Zealand, Singapore, South Africa, UK, USA)
Estonian (Estonia)
Finnish (Finland)
French (Belgium, Canada, France, Switzerland)
German (Austria, Germany, Switzerland)
Greek (Greece)
Gujarati (India)
Hebrew (Israel)
Hindi (India)
Hungarian (Hungary)
Italian (Italy, Switzerland)
Japanese (Japan)
Kannada (India)
Korean (Korea)
Latvian (Latvia)
Lithuanian (Lithuanian)
Malay (Malaysia, Singapore)
Malayalam (India)
Marathi (India)
Norwegian (Norway)
Polish (Poland)
Portuguese (Brazil, Portugal)
Romanian (Romania)
(continued)
(continued)
Russian (Estonia, Israel, Latvia, Lithuania, Russia, Ukraine)
Serbian (Serbia)
Slovak (Slovakia)
Spanish (Argentina, Chile, Mexico, Peru, Puerto Rico, Spain, US)
Swedish (Finland, Sweden)
Tagalog (Philippines)
Tamil (India, Singapore)
Telugu (India)
Thai (Thailand)
Turkish (Turkey)
Ukrainian (Ukraine)
Urdu (India)
Xhosa (South Africa)
Latest update: April 2012
256 Appendix 4: EQ-5D-5L Language Versions
Appendix 5: EQ-5D-Y Language Versions
Dutch (Belgium, the Netherlands)
English (Canada, UK)
French (Belgium)
German (Austria, Germany)
Italian (Italy)
Polish (Poland)
Spanish (Spain)
Swedish (Sweden)
Xhosa (South Africa)
Latest update: February 2012
257
Appendix 6: Present EuroQol Members
Liv Ariane Augestad Claire Gudex Kim Rand-Hendriksen
Xavier Badia Narcis Gusi Ulrike Ravens-Sieberer
Henry Bailey Michael Herdman Luciana Scalone
Stefan Bj€ork Bas Janssen Kristina Secnik Boye
Gouke Bonsel Jennifer Jelsma Caroline Selai
John Brazier Jeff Johnson James Shaw
Richard Brooks Paul Kind Harri Sintonen
Stirling Bryan Thomas Kohlmann Caitlyn Solem
Kristina Burstr€om Maria Koltowska-H€aggstr€om Barbara Spady
Jan Busschbach Paul Krabbe Peep Stalmeier
Martin Buxton Anna Krabbe Lugner Knut Stavem
Juan Casabes Leida Lamers Elly Stolk
Guilia Cavrini Andrew Lloyd Sun Sun
Julie Chevalier Louise Longworth Agota Szende
Ling-Hsiang Chuang Erica Lubetkin Sally Thompson
Johannes Clouth Nan Luo Carlo Tomasetto
Stephen Coons Lorenzo Mantovani Aki Tsuchiya
Benjamin Craig Arto Ohinmaa Ben van Hout
Frank de Charro Mark Oppe Nora Wille
Gerard de Pouvourville David Parkin Feng Xie
Sarah Derrett Simon Pickard John Yfantopoulos
Nancy Devlin Valentina Prevolnik Rupel Victor Zarate
Ann-Charlotte Egmar Rosalind Rabin
Dominik Golicki Juan Manuel Ramos-Goni
Wofgang Greiner
Ning Yan Gu
259
Appendix 7: Attendance at the Early Meetings
Meeting Name Commentary
1st Rotterdam May
1987
Martin Buxton, Joy Ashby{, Frank de
Charro, Paul van der Maas, Ben
van Hout, Gouke Bonsel, Yvonne
Spronk, Ronald Bergman, Carole
Butler, Bjorn Lindgren, Ulf Persson,
Alan Williams{, Paul Kind, Claire
Gudex
Yvonne Spronk and Ronald
Bergman did not re-attend.
Carole Butler left after 6th.
2nd Brunel
October 1987
New: Markku Pekurinen, Harri
Sintonen, Jeremy Hurst, Rosalind
Rabin, Rachel Rosser{, Julia
Rushby
Jeremy Hurst left after 5th
3rd Brunel January
1988
New: Richard Allison Richard Allison left after 6th
4th Brunel July
1988
New: Erik Nord, Richard Brooks
5th Brunel July
1989
New: Moira O’Hanlon, Stefan Bj€ork,Stefan Jendteg, Joanna Mulvey,
Marie-Louise Essink-Bot, Jenny
Morris
Only appearances: Joanna
Mulvey, Jenny Morris, Stefan
Jendteg
6th Rotterdam
January 1990
New: Emile van Lin, Caroline Selai Only appearance: Emile van Lin.
7th York
September
1990
New: Jan van Busschbach, David
Parkin, Henry Neuburger
Henry Neuburger attended Lund
1991, but not thereafter.
Notes: Names in bold remain members 2012{Deceased
261
Appendix 8: Individuals Listed in Health PolicyArticle 1990
Martin Buxton, Moira O’Hanlon, Julia Rushby, Markku Pekurinen, Harri Sintonen, Stefan
Bj€ork, Bj€orn Lindgren, Ulf Persson, Richard Brooks, Erik Nord, Richard Allison, Carole Butler,
Rosalind Rabin, Rachel Rosser{, Caroline Selai, Gouke Bonsel, Marie Louise Essink-Bot, Ben
van Hout, Frank de Charro, Claire Gudex, Paul Kind, Alan Williams{.
Notes: Names in bold remain members 2012{Deceased
Bj€orn Lindgren and Ulf Persson left after Lund meeting 1991
263
Appendix 9: Membership 1995 Onwards
265
Year Membership Commentary
1995 Xavier Badia, Stefan Bj€ork, Gouke
Bonsel, Richard Brooks, Jan van
Busschbach, Martin Buxton, Juan
Cabases, Frank de Charro, Paul
Dolan, Marie Louise Essink-Bot, Julia
Fox-Rushby, Idoia Gaminde,
Wolfgang Greiner, Claire Gudex,
Ben van Hout, Paul Kind, Paul
Krabbe, Erik Nord, Moira O’Hanlon,
Arto Ohinmaa, David Parkin Jose
Luis Pinto, Rosalind Rabin, Rachel
Rosser{, Caroline Selai, Harri
Sintonen, Alan Williams{, Ardine de
Wit, John Yfantopoulos
Associate Membership: Markku
Pekurinen, Paul van der Maas,
Matthias Graf vd Schulenburg, Frans
Rutten
Individual membership was instituted at
Barcelona Plenary Meeting.
In 1992 Paul Krabbe had joined as a
member of the Dutch group, Paul
Dolan from York, and Pontus Roos
from Sweden. In 1993 Xavier Badia
was the first from Spain, Arto
Ohinmaa joined from Finland, and
Frans Rutten attended from the
Netherlands. Jose Luis Pinto joined
from Spain in 1994.
..
1996 New: Jeffrey Johnson, Stephen Coons,
Pontus Roos{Moira O’Hanlon formally retired from
Group.
1997 New: Michael Herdman, Nancy Mayo
1998 New: Naoki Ikegami, Montserrat Roset,
Knut Stavem
1999 New: Stirling Bryan, Wendy Coucill,
Barbara Conner Spady, Andrew
Lloyd, Aki Tsuchiya, Martin
Wildman
Left: Jose Luis Pinto.
2000 New: Nancy Devlin, Marthe Gold, Paul
Hansen, Jenny Jelsma, Louise
Longworth, Sue Macran, Madhav
Namjoshi, Simon Pickard, Valentina
Prevolnik Rupel, Agote Szende,
Sally Thompson
(continued)
(continued)
Year Membership Commentary
2001 New: Kristina Burstr€om, Paulo Campos,
Sarah Derrett, Cristina Granja,
Narcıs Gusi, Thomas Kohlmann,
Erica Lubetkin, Anna Norinder,
Matekja Rebolj, Tommy Oberg{,Ulrika Oberg, Kjeld Møller Pedersen
2002 Left: Ardine de Wit
2003 New: Nan Luo
2004 New: Leida Lamers, Kristina Secnik,
James Shaw
Membership lapsed: Paulo Campos, Paul
Dolan, Julia Fox-Rushby, Christina
Granja, Paul Hansen, Naoki Ikegami,
Kjeld Moeller Pedersen, Montserrat
Roset, Martin Wildman. Associate
members: Paul van der Maas, Markku
Pekurinen, Frans Rutten and J.-
Matthias Graf v.d.Schulenburg.
2005 New: Guilia Cavrini, Luciana Scalone
2006 New: Bas Janssen, Barbara Pacelli, PeepStalmeier
2007 New: Nuria Lara, Mark Oppe, Maria
Koltowska-H€aggstr€om, Nora Wille
Membership lapsed: Madhav Namjoshi,
Nancy Mayo.
2008 New: Ling-Hsiang Chuang, Johannes
Clouth, Benjamin Craig, Ann-
Charlotte Egmar, Ulrike Ravens-
Sieberer, Sun Sun, Carlo Tomasetto,
Victor Zarate
Membership lapsed: Marthe Gold.
2009 New: Lorenzo Mantovani, Elly Stolk.
2010 New: Henry Bailey, John Brazier, Julie
Chevalier, Dominik Golicki, Ning
Yan Gu, Gerard de Pouvourville,
Caitlyn Solem (Wilke), Feng Xie
Membership lapsed: Susan Macran van
Hout, Ulrika Oberg.
2011 Membership lapsed: Idoia Gaminde,
Nuria Lara, Barbara Pacelli, Matejka
Rebolj.
2012 New: Juan Manuel Ramos-Goni, Kim
Rand Hendriksen, Liv Ariane
Augestad
Notes: Names in bold remain members 2012{Deceased
266 Appendix 9: Membership 1995 Onwards
Appendix 10: Child-Related Papers
Method Papers
Burstr€om, K., Egmar, A.-C., Lugner, A., Eriksson, M., Svartengren, M. (2011):
A Swedish child-friendly pilot version of the EQ-5D instrument - the develop-
ment process. European Journal of Public Health; 21(2):171–7
Gusi, N., Badıa, X., Herdman, M., Olivares, P.R. (2009):Translation and cultural
adaptation of the Spanish version of EQ-5D-Y questionnaire for children and
adolescents. Atencionprimaria; 41(1): 19–23.
Ungar, W. J. (2011): Challenges in health state valuation in pediatric economic
evaluation: are QALYs contraindicated? Pharmacoeconomics; 29(8): 641-52.
Wille, N., Badia, X., Bonsel, G., Burstr€om, K., Cavrini, G., Devlin, N., Egmar, A.-C.,
Greiner, W., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Scalone, L., Ravens-
Sieberer, U. (2010): Development of the EQ-5D-Y: a child-friendly version of
the EQ-5D. Quality of Life Research; 19(6):887–97.
Validation Studies
Eidt-Koch, D., Mittendorf, T., Greiner, W. (2009): Cross-sectional validity of the
EQ-5D-Y as a generic health outcome instrument in children and adolescents
with cystic fibrosis in Germany. BMC Pediatrics; 9:55.
Ravens-Sieberer, U., Wille, N., Badia, X., Bonsel, G., Burstrom, K., Cavrini, G.,
Devlin, N., Egmar, A.-C., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Olivares
P.R., Scalone, L., Greiner, W. (2010): Feasibility, reliability, and validity of the
EQ-5D-Y: results from a multinational study. Quality of Life Research; 19(6):
887–97.
267
Application of EQ-5D-Y
Boyle, S. E., Jones, G. L., Walters, S. J. (2010): Physical activity, quality of life,
weight status and diet in adolescents. Quality of Life Research; 19(7): 943-54.
Burstr€om, K., Svartengren, M., Egmar, A.-C. (2011): Testing a Swedish child-
friendly pilot version of the EQ-5D instrument – initial results. European Journal
of Public Health; 21(2): 178-83.
Jelsma, J. (2010): A comparison of the performance of the EQ-5D and the
EQ-5D-Y health-related quality of life instruments in South African children.
International Journal of Rehabilitation Research; 33(2):172-7.
Jelsma, J., Ramma, L. (2010): How do children at special schools and their parents
perceive their HRQoL compared to children at open schools? Health and Quality
of Life Outcomes; 8:72.
Nordyke, K., Norstr€om, F., Lindholm, L., Carlsson, A., Danielsson, L., Emmelin,
M., H€ogberg, L., Karlsson, E., Ivarsson, A. (2011): Health-related quality-of-lifein children with coeliac disease, measured prior to receiving their diagnosis
through screening. Journal of Medical Screening; 18(4):187-92.
Oluboyede, Y., Tubeuf, S., McCabe, C. (2011): Measuring health outcomes of
adolescents: report from a pilot study. European Journal of Health Economics;
online first, July 2011.
Willems, D. C., Joore, M. A., Nieman, F. H., Severens, J. L., Wouters, E. F.,
Hendriks, J. J. (2009): Using EQ-5D in children with asthma, rheumatic
disorders, diabetes, and speech/language and/or hearing disorders. International
Journal of Technology Assessment in Health Care; 25(3): 391-9.
Wu, X.Y., Ohinmaa, A., Veugelers, P.J. (2012): Diet quality, physical activity,
body weight and health-related quality of life among grade 5 students in Canada.
Public Health Nutrition; 15(1): 75-81.
Wu, X. Y., Ohinmaa, A., Veugelers, P. J. (2010): Sociodemographic and neighbor-
hood determinants of health-related quality of life among grade-five students in
Canada. Quality of Life Research; 19(7):969-76.
Burstr€om K., Egmar A-C., Sun S., Eriksson M., Svartengren M. (2010): Utveckling
av EQ-5D-Y – en barnv€anlig version av det h€alsorelaterade livskvalitetsin-
strumentet EQ-5D. (Development of EQ-5D – a child-friendly version of the
health-related quality of life instrument EQ-5D.) Stockholm: Karolinska
Institutets Folkh€alsoakademi, 2010. Rapport 2010:22. (Karolinska Institutet
School of Public Health, 2010. Report 2010:22.) (In Swedish).
Review
Noyes, J., Edwards, R.T. (2011): EQ-5D for the assessment of health-related
quality of life and resource allocation in children. A systematic methodological
review. Value in Health; 14(8):1117-29.
268 Appendix 10: Child-Related Papers
Further Publication
Scalone, L., Tomasetto, C., Matteucci, M.C., Selleri, P., Broccoli, S., Pacelli, B.,
Cavrini, G. (2011): Assessing quality of life in children and adolescents: Devel-
opment and validation of the Italian version of the EQ-5D-Y. Italian Journal of
Public Health; 8(4): 331-341.
Appendix 10: Child-Related Papers 269
References
Abdalla M and Russell I. Tariffs for the EuroQol health states based on modelling the individual
VAS and TTO data of the York survey. In O’Hanlon and Buxton (1995).
Alli M, Ibrahim M, Lawrence D, Lockhart J, Laitner S, Brogan C. Survey on tackling health
inequalities amongst older people in Brent and Harrow district of the UK: results from EQ-5D
questionnaire. In Kind and Macran (2002a).
Angelsen V and Olsen J. QALY-league tables for a hospital. In O’Hanlon and Buxton (1995).
Arons A and Krabbe P. Considering cognition as a bolt-on dimension for the EQ-5D. Paper
presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September
2011.
Attema A, Versteegh M, Oppe M, Brouwer W, Stolk E. Lead time TTO: leading to better health
state valuations? In Yfantopoulos (2010).
Augestad L, Rand-Hendriksen K, Kristiansen I, Stavem K. Learning effects in EQ-5D TTO
valuation. In Yfantopoulos (2010).
Augustovski F, Irazola V, Velazquez A, Gibbbons L, Craig B. To develop a set of EQ-5D health
state values for the Argentine general population. In Scalone and Mantovani (2008).
Badia X. (Ed.) 25th Scientific Plenary Meeting of the EuroQol Group, September 2006, Barcelona.
IMS Health Barcelona, 2007.
Badia X, Femandez E, Segura, A. Influence of socio-demographic and health status variables on
evaluation of health states in a Spanish population. European Journal of Public Health 1995a;
5:87–93.
Badia X, Herdman M, Segura A. (Eds.). EuroQol Plenary Meeting Barcelona October 1995.
Institut Universitari de Salut Publica de Catalunya, 1996.
Badia X, Herdman M, Roset M. (Eds.). 16th Plenary Meeting of the EuroQol Group Discussion
Papers, Sitges, Spain, November 1999. Institut Universitari de Salut Publica de Catalunya,
2000.
Badia X, Roset M, Perulero N. Validation of the EQ-5D to be used in children with persistent
asthma. In Pickard (2004).
Badia X, Roset M, Sara M, Herdman M. The Spanish VAS tariff based on valuations of EQ-5D
health states from the general population. In Rabin et al (1998).Badia X, Saez M, Pinto JL. Is the EuroQol data produced in an interval scale? Applying method of
successive intervals with the Spanish EuroQol data. In O’Hanlon and Buxton (1995b).
Bailey H and Kind P. An evaluation of some approaches to the design of discrete choice
experiments to elicit EQ-5D health state valuations. In Scalone and Mantovani (2008).
Bailey H and Kind P. Does time trade-off capture ‘true’ preferences for EQ-5D health states? In de
Pouvourville (2009).
R. Brooks, The EuroQol Group after 25 years, DOI 10.1007/978-94-007-5158-3,# Springer Science+Business Media Dordrecht 2013
271
Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic
evaluations and quality-of-life studies related to generalized anxiety disorder. Clinical Thera-
peutics 2009;31:1279–308.
Bergner M, Bobitt R, Kressel S, Pollard W, Gilson B, Morris J. The Sickness Impact Profile:
conceptual formulation and methodology for the development of a health status measure.
International Journal of Health Services 1976; 6:393–415.
Betegon L and Badia X. Discussion paper review of the use of the EQ-5D in cost-utility analysis.
In Badia (2007).
Bj€ork S. (Ed.) EuroQol Conference Proceedings, Lund, October 1991. Swedish Institute for HealthEconomics, 1992.
Bj€ork S and Althin R. Health states considered worse than being dead. In Bj€ork (1992).
Bj€ork S and Norinder A. The weighting exercise for the Swedish version of the EuroQol.
In O’Hanlon and Buxton (1995).
Bonsel G. One tariff for EuroQol – methodological issues relevant for the modelling of EuroQol
data. In O’Hanlon and Buxton (1995).
Bonsel G. The utility of public health. Paper given at the Second Annual Meeting of Health
Technology Assessment International, Rome, 2005.
Brazier J, Roberts J, Tsuchiya A. A comparison of the EQ-5D and SF-6D across seven patient
groups. In Norinder et al (2002).Brooks R with the EuroQol Group. EuroQol: the current state of play. Health Policy 1996;
37:53–72.
Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status using EQ-5D:
A European Perspective. Kluwer. 2003.
Bryan S and Longworth L. EQ-5D versus SF-6D: why the disparity? In Kind and Macran (2002).
Bryan S, Jowett S, Hardyman W, Bentham P. Does the EQ-5D “anxiety/depression” item measure
anxiety, depression, both or neither? In Pickard (2004).
Buckingham K, Devlin N, Hansen P. Does it matter whose valuations are used to estimate health
state tariffs, and which tariffs are used for CUA? In Cabases and Gaminde (2001)
Busschbach Jv. De Validiteit van QALYs. Gouda Quint, Arnhem, 1994.
Busschbach Jv, Bonsel G, de Charro F. (Eds.) EuroQol Plenary Meeting Rotterdam October 1993.
Erasmus University, 1994.
Busschbach J, Rabin R, de Charro F. (Eds.) 24th Scientific Plenary Meeting of the EuroQol
Group Proceedings, Kijkduin–The Hague, the Netherlands, September 2007. EuroQol Group
Executive Office, 2007.
Busschbach Jv, Hessing D, de Charro, F. An empirical comparison of four measurements of
quality of life: standard gamble, time trade-off, the Euroqol visual analog scale and the Rosser
& Kind matrix. In Sintonen (1993).
Busschbach Jv, McDonnell J, van Hout B. Testing different parametric relations between the
EuroQol health description and health valuations in students. In Nord (1997a).
Busschbach J, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Dolan P, Greiner W, Kind P,
Krabbe P, Ohinmaa A, Roset M, Sintonen H, Tsuchiya A, Williams A, Yfantopoulos J,
de Charro F. A comparison of EQ-5D time trade-off values obtained in Germany, the United
Kingdom and Spain. In Brooks et al (2003).Cabases JM and Gaminde I. (Eds.) 17th Plenary Meeting of the EuroQol Group Discussion Papers,
Pamplona, Spain, September 2000. Universidad Publica de Navarra, 2001.
Cabases J and Sanchez E. Valuation of 5-level states and back-compatibility with existing 3-level
valuation sets: a Bayesian approach. In Stavem (2005).
Cabases J, Gaminde I, Ugalde J, Pozo F. Social elicitation of EQ-5D health states preferences
through person Trade off (PTO). In Cabases and Gaminde (2001).
Cadenas E, Perulero N, Lizan L, Badia X. The use of the EQ-5D in patients with osteoporosis.
In Badia (2007).
Carr-Hill R. Health related quality of life measurement–Euro style. Health Policy 1992;
20:321–328.
Chevalier J, Devlin N, Parkin D, de Pouvourville G. Comparison of the VAS questionnaire and an
experimental scoring method. In de Pouvourville (2009).
272 References
Chevalier J and de Pouvourville G. Testing of a new 5 level version of the EQ-5D in France.In Scalone and Mantovani (2008).
Chevalier J and de Pouvourville G. Valuing EQ-5D using Time Trade-Off in France. In de
Pouvourville (2009).
Chuang L. Estimating domestic values for EQ-5D health states using imported national survey
data. In Busschbach et al (2007).Chuang L and Kind P. The effect of EQ-5D health state selection in the valuation. In Busschbach
et al (2007).Chuang L, Weatherly H, Kind P. The role of ranking in the EQ-5D valuation protocol. In de
Pouvourville (2009).
Chuang L, Zarate V, Kind P. The distribution of values for health. In Scalone and Mantovani
(2008).
Chuck A, Ohinmaa A, Adamowicz W, Jacobs P, Dick B, Rashiq S. Is there an association between
Willingness to Pay and the EQ-5D Index Score? In Busschbach et al (2007).Claes C, Greiner W, Uber A, Graf v.d. Schulenberg J-M. An interview-based comparison of the
TTO and VAS values given to EuroQol states of health by the general German population.
In Greiner et al (1999).Claes C, Greiner W, Uber A, Graf v.d. Schulenberg J-M. The new German version of the EuroQol
quality of life questionnaire. In Rabin et al (1998).Clayson D, Wild D, Quarterman P, Duprat-Lomon I, Kubin M, Coons S. A comparative review of
health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoe-
conomics 2006; 24:751–65.
Cleemput I, Kind P, Kesteloot K. Re-scaling social preference data: implications for modelling.
In Kind and Macran (2002a).
Cleemput I, Kesteloot K, Moons P, Vanrenterghem Y, Van Hooff J, Squifflet J, Clouth J,
Schmidt P, M€oser G, Greiner W. Estimating EQ-5D utilities applying structural equation
modelling (SEM) for the German population. In Busschbach et al (2007).Coons S and Johnson J. Comparison of the EQ-5D and SF-12 in an adult US-based population
sample. In Nord (1997a).
Craig B. From a different angle: a novel approach to health valuation. In de Pouvourville (2009).
Craig B and Busschbach J. Replacing ad hoc adjustments for TTO values below death with a
consistent theoretical model: increasing validity and power. In Scalone and Mantovani (2008).
Craig B and Pickard AS. Variability in QALY values for chronic conditions. In de Pouvourville
(2009).
Craig B, Busschbach J, Salomon J. Ordinal valuation of health states: a seven country comparison.
In Badia (2007a).
Craig B, Busschbach J, Salomon J. International valuation set for EQ-5D health states.
In Busschbach et al (2007b).de Charro F, Busschbach Jv, Essink-Bot M-L, van Hout B, Krabbe P. Some considerations about
negative health states for EQ-5D health states. In Badia et al (1996).de Haan R, Aaronson N, Limburg M, Hewer R, van Crevel H. Measuring quality of life in stroke.
Stroke 1993; 24:320–7.
de Pouvourville G. (Ed.) 26th Scientific Plenary Meeting of the EuroQol Group Proceedings, Paris,
France, September 2009. EuroQol Group Executive Office, 2009.
de Wit A, Merkus M, de Charro F. Measuring utilities in an end-stage renal disease population.
In Badia et al (1996).de Wit A, Busschbach Jv, de Charro F. Sensitivity and perspective in the valuation of health status:
whose values count? In Greiner et al (1999).Department of Health. The NHS Outcomes Framework 2011/12. NHS Department of Health
(2010).
Derrett S, Black J, Herbison G. Outcome after injury: a systematic literature search of studies using
the EQ-5D. Journal of Trauma 2009; 67:883–90.
References 273
Derrett S, Black J, Herbison G. EQ-5D and injury: a systematic review. In Scalone and Mantovani
(2008).
Devlin N and Parkin D. Guidance to users of EQ-5D value sets. In Szende et al (2007).Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G, van Hout B. A compari-
son of alternative variants of the lead and lag time TTO. In Yfantopoulos (2010).
Devlin N, Hansen P, Kind P, Williams A. The health state preferences and logical consistencies of
New Zealanders: a tale of two tariffs. In Cabases and Gaminde (2001).
Devlin N, Hansen P, Selai C. Respondents’ perception of an EQ-5D valuation questionnaire:
insights from a self-completed VAS survey. In Norinder et al (2002a).Devlin N, Hansen P, Macran S. A “new and improved” EQ-5D valuation questionnaire?: Results
from a pilot study. In Kind and Macran (2002b).
Devlin N, Parkin D, Browne J. Using the EQ-5D as a performance measurement tool in the NHS.
In Scalone and Mantovani (2008).
Dolan P. Search for a critical appraisal of EuroQol: a response by the EuroQol Group to Gafni and
Birch. Health Policy 1994; 28:67–69.
Dolan P. Modelling valuations for EuroQol health states. In O’Hanlon and Buxton (1995).
Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general
population survey. Discussion Paper 138, Centre for Health Economics, York, 1995.
Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. Journal of
Health Economics 1996a; 15:209–231.
Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general
population study. Health Economics 1996b; 5:141–154.
Dyer M, Goldsmith K, Sharples L, Buxton M. A review of health utilities using the EQ-5D in
studies of cardiovascular disease. Health and Quality of Life Outcomes. 2010; 28; 8:13.
Elliott V, Rodgers D, Brett S. Systematic review of quality of life and other patient-centred
outcomes after cardiac arrest survival. Resuscitation 2011; 82:247–56.
Essink-Bot M-L and Bonsel G. A common core for utility measurement: The Bergen op Zoom
Survey. Institute for Medical Technology Assessment, Rotterdam, 1989.
F€are R, Grosskopf S, Roos P. Comparing states of health. In Stavem (2005).
Fox-Rushby J. First steps to assessing semantic equivalence of EQ-5D: Results of a questionnaire
survey to members of the EuroQol Group. In Nord (1997)
Fox-Rushby J and Badia X. Reviewing international language versions of the EuroQol Instrument:
challenges for the future. In Badia et al (1996).Fox-Rushby J and Selai C. What concepts does the EQ-5D measure? Intentions and
interpretations. In Brooks et al (2003).Fukuda T, Hamashima C, Hisashige A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Tamura M,
Tsuchiya A. Estimating a EuroQol value set: the case of Japan. In Badia et al (2000).Gaebel K, Pullenayegum E, Krabbe P, Oppe M, Xie F. Use of Discrete Choice Experiment in
measuring preferences: binary or triplet? Paper presented at the 28th Scientific Plenary Meeting
of the EuroQol Group, Oxford, September 2011.
Gafni A and Birch S. Searching for a common currency: critical appraisal of the scientific basis
underlying European harmonization of the measurement of health related quality of life
(EuroQol). Health Policy 1993; 23(3):219–228.
Gaminde I and Cabases J. Measuring valuations for health states amongst the general population in
Navarra (Spain). In Badia et al (1996).Gharagebakyan G, Ghukasyan H, Williams A, Szende A. Social inequalities in self-reported
health: is Armenia different from Slovenia? In Prevolnik Rupel (2003).
Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach J. Valuing EQ-5D with time trade-
off for the Polish population. In Scalone and Mantovani (2008).
Golicki D, Zawodnik S, Janssen M, Kiljan A, Hermanowski T. Psychometric comparison of
EQ-5D and EQ-5D-5L in student population. In Yfantopoulos (2010).
Graf vd Schulenberg J-M, Claes C, Greiner W, Uber A. The German version of the EuroQol
Quality of Life Questionnaire. In Badia et al (1996).
274 References
Greiner W, Graf v.d. Schulenberg J-M, Piercy J. (Eds.) EuroQol Plenary Meeting Hannover
October 1998 Discussion Papers. Uni-Verlag Witte, 1999.
Greiner W,Weijnen T, Nieuwenhuizen M, Oppe S, de Charro F. A European EQ-5D valuation set.
In Brooks et al (2003).Gu NY, Craig B, Doctor J. Evaluating EQ-5D items using the Rasch Models in a U.S. representa-
tive sample. In Scalone and Mantovani (2008).
Gudex C. Are we lacking a dimension of energy in the EuroQol Instrument? In Bj€ork (1992).
Gudex C. The descriptive system of the EuroQol Instrument. In Badia et al (1996).Gudex C and MacDonagh R. Change in reported health status following urological surgery:
preliminary results. In Busschbach et al (1994).Gudex C, Kind P, Dolan P. The valuation of death. In Sintonen (1993).
Gusi N, Ortega Y, Garcıa-Martin Y, Monge M. Physical activity, lifestyle and health-related
quality of life of secondary students in Extremadura, Spain. In Norinder et al (2002).Haagsma J, Janssen B, Bonsel G. Comparing generic and disease specific health state valuations
by a laymen panel. In Stavem (2005).
Hare J, Leese B, Hardman G. Applications of EuroQol (EQ5D) in general practice: an exploratory
study. In Rabin et al (1998).Hennessy S and Kind P. Measuring health status in children: developing and testing a child-
friendly version of EQ-5D. In Kind and Macran (2002a).
Herdman M, Fox-Rushby J, Rabin R, Badia X, Selai C. Producing other language versions of the
EQ-5D. In Brooks et al (2003).Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development
and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life
Research 2011; 20:1727–1736.
Herdman M, Kind P. Chevalier J, Gudex C, de Pourvourville G. Investigation of labels for
additional EQ-5D levels: Results of main study + 1. In Busschbach et al (2007).Herdman M, Sanz L, Lloyd A, Badia X, Gudex, C. Qualitative testing of two new 5-level versions
of the EQ-5D in Spain: Preliminary study results. In Scalone and Mantovani (2008).
Hunt S and McEwen J. The development of a subjective health indicator. Social Health and Illness
1980; 2:231–246.
Ikeda S, Sakai I, Tamura M, Tsuchiya A. VAS valuations of hypothetical health states in Japan.
In Cabases and Gaminde (2001).
Ikegami N, and Ikeda S. Health status in the Japanese population: results from the Japanese
EuroQol study. In Badia et al (2000).Janssen M. The discriminatory power of the EQ-5D, HU12, HU13 and the SF-6D in 13 patient
groups. In Busschbach et al (2007).Janssen M and Bonsel G. Towards a HUI-fication of the EQ descriptive system: should the EQ
descriptive system be extended from three to five levels? A universal modelling strategy with
an empirical pilot. In Pickard (2004).
Janssen M, Haagsma J, Bonsel G. Comparing the standard EQ-5D three level system with a five
level version. In Stavem (2005).
Janssen M, Birnie E, Bonsel G. Quantification of the level descriptors for the standard EQ-5D three
level system and a five level version according to 2 methods. Quality of Life Research
2008a;17:463–473.
Janssen M, Birnie E, Bonsel G. Quantification of the level descriptors for the standard EQ-5D three
level system and a five level version according to 2 methods. In Badia (2007).
Janssen M, Birnie E, Haagsma J, Bonsel G. Comparing the standard EQ–5D three level system
with a five level version. Value in Health. 2008b;11:275–284.
Janssen M, Busschbach J, Golicki D, Niewada M, Scalone L, Swinburn P, Pickard AS. Measure-
ment properties of the EQ-5D-5L compared to EQ-5D-3L in 8 patient groups. Paper presented
at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011b.
Janssen M, Gorts R, Hazenberg C, Krabbe P. Discrepancies between the EQ-5D societal index and
patient derived valuations. In Prevolnik Rupel (2003).
References 275
Janssen M, Lubetkin E, Pickard AS. The use of the EQ-5D preference-based health status measure
in adults with type 2 diabetes mellitus. In de Pouvourville (2009).
Janssen M and Bonsel G. Estimating preference weights for chronic multimorbidity: Don’t add,
multiply. In Scalone and Mantovani (2008).
Janssen M, Lubetkin E, Sekhobo J, Pickard AS. The use of the EQ-5D preference-based health
status measure in adults with Type 2 diabetes mellitus. Diabetic Medicine 2011a; 28:395–413.
Jelsma J and Matyida N. The development of an adapted version of the EQ-5D for infants under
the age of 36 months. In Prevolnik Rupel (2003).
Jelsma J and Ferguson G. The determinants of HRQoL in able-bodied and disabled children. In de
Pouvourville (2009).
Johnson J, Ohinmaa A, Murti B, Sintonen H, Coon S. Comparison of Finnish and US-based visual
analog scale valuations of the EQ-5D measure. Medical Decision Making 2000; 20:281–289.
Johnson J, Ergo A, Coons S. Valuation of the EuroQol (EQ-5D) in an adult US sample. In Nord
(1997a).
Johnson J, Luo N, Shaw J, Kind P, Coons S. Valuations of EQ-5D health states: are the US and
UK different? In Pickard (2004).
Kaplan R, Bush J, Berry C. Health status: types of validity and the index of wellbeing. Health
Services Research 1976; 11:478–507.
Karnofsky D and Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer.
In Macleod C. Evaluation of Chemotherapeutic Agents. Columbia UP, 1949.
Kerim-Sade C, and Wasem J. An external control of the validity of the German EQ-5D question-
naire. In Badia et al (2000).
Kind P. Foreword. In Kind P et al (2005a).Kind P. Forging the link between VAS and TTO: Is this the end for utility measurement?
In Norinder et al (2002).Kind P. In Memoriam: Alan Williams (1928�2005). Value in Health 2005c; 8: 615–617.
Kind P. Valuing EQ-5D health states – a VAStly simpler solution? In Busschbach et al (2007).Kind P. Valuing health benefits using EQ-5D: the W Lothian question. In Stavem (2005b).
Kind P and Gudex C. Measuring health status in the community: a comparison of methods. Journal
of Epidemiology and Community Health 1991; 48:86–91.
Kind P and Macran S. (Eds.) 19th Plenary Meeting of the EuroQol Group Discussion Papers, York,
UK, September 2002. Centre for Health Economics, University of York, 2002a.
Kind P and Macran S. Levelling the playing field: increasing the number of response categories in
EQ-5D. In Kind and Macran, 2002b.
Kind P, Brooks R, Rabin R (Eds.) EQ-5D Concepts and Methods. Kluwer, 2005.
Kind P, Hennessy S, Macran S. The value of hypothetical and “real” EQ-5D health states and other
things: a fairytale for the childrens’ session at the EuroQol Scientific Plenary. In Pickard
(2004).
Kind P, Leese B, Hardman G. Demonstrating the value of EQ-5D as a tool for monitoring health
status in primary care. In Rabin et al (1998).Kind P, Macran S, Hennessy S. Measuring social preferences for EQ-5D health states: results from
a saturation study. In Prevolnik Rupel (2003).
Klose, K and Greiner W.: Developing a cognitive dimension as a bolt-on for the EQ-5D-Y in
Germany. Poster presented at the 28th Scientific Plenary Meeting, Oxford, UK, September
2011.
Kohlmann T, Gnanasakthy A, Naujoks C. Are category scores for EQ-5D derived from
psychometric models equivalent to the results of preference-based valuations? In Norinder
et al (2002).Kok E, Stolk E, Busschbach Jv. Influences of the number of health states on time trade-off.
In Cabases and Gaminde (2001).
Krabbe P. Good day sunshine: about biases, irregularities and inconsistencies in valuation of
health states. In Kind and Macran (2002a).
276 References
Krabbe P. Revealing preference patterns of health states with singular value decomposition.
In Prevolnik Rupel (2003).
Krabbe P. Thurstone scaling as a measurement method to derive health-state quantifications.
In Stavem (2005).
Krabbe P, Bonsel G, Essink-Bot M-L. Modelling: multiple classification analyse and logit
transformation. In O’Hanlon and Buxton (1995).
Krabbe P, de Charro F, Essink-Bot M-L. Issues in the harmonisation of valuation and modelling.
In Badia et al (1996).Krabbe P, Stalmeier P, Lamers L, Busschbach Jv. An experimental study on three principal biases
of the visual analogue scale. In Pickard (2004).
Krabbe P, Stouthard M, Esssink-Bot M-L, Bonsel G. The effect of adding a cognitive dimension to
the EuroQol multi-attribute health status classification system. In Rabin et al (1998).Krabbe P, Stouthard M, Esssink-Bot M-L, Bonsel G. The effect of adding a cognitive dimension
to the EuroQol multi-attribute health status classification system. Journal of Clinical Epidemi-
ology 1999; 52:293–301.
Krabbe P. Presentation of design, methods and ‘common core’ results of the multi-country study,
parts 1 and 2. Papers presented at the 28th Scientific Plenary meeting of the EuroQol Group,
Oxford, September 2011.
Lai T. Computer assisted interview collection and fully electronic management of EQ data in
Estonia. In Pickard (2004).
Lamers L. Adjustment of EQ-5D TTO valuation sets for use of an EQ-5D five level descriptive
system: a pragmatic approach. In Stavem (2005).
Lamers L, McDonnell J, Stalmeier P, Krabbe P, Busschbach J. A Dutch value set for the EQ-5D:
first results. In Prevolnik Rupel (2003).
Leese B, Kind P, Hardman G. Measuring outcomes – managing performance: roles for EQ-5D in
delivering primary health care services? In Kind and Macran (2002a).
Lloyd A and Quadri N. Testing alternative labels for a UK English five level version of EQ-5D.In Scalone and Mantovani (2008).
Lloyd A, Nafees B, Rousculp M, Secnik-Boye K. Rich versus simple descriptive systems: does it
make any difference? In Busschbach et al (2007).Lloyd A, Swinburn P, Edson E, Bowman L, Boye K, Janssen M, Pickard AS, de Charro F.
Development of the EQ-5D-Psoriasis. In Yfantopoulos (2010).
Luo N, Johnson J, Shaw J, Coon S. Relative efficiency of the EQ-5D, HU12, and HU13 in a US
population survey. In Pickard (2004).
Luo N, Li M, Liu G. Investigation of labels for a 5-level EQ-5D descriptive system in Chinese.
In de Pouvourville (2009).
Luo N, Li M, Liu G, Lloyd A, de Charro F, Herdman M. Developing the Chinese version of the
new 5-level EQ-5D descriptive system: the response scaling approach. Quality of Life
Research (2012).
Macran S. Recalled versus initial health status: EQ-5D in retrospect. In Kind and Macran (2002a).
Macran S. The relationship between religious belief and values for the state dead. In Prevolnik
Rupel (2003).
Macran S and Kind P. An Illness Atlas for EQ-5D. In Stavem (2005).
Macran S and Kind P. EQ-5D valuations from a British national postal survey. In Cabases and
Gaminde (2001)
Macran S and Kind P. Valuing EQ-5D health states using a modified MVH protocol: preliminary
results. In Badia et al (2000).Manninen M, Ohinmaa A, Winblad I, Remes A, Viramo P, Liuska E, Hynninen, M. Health-related
quality of life of care-givers of dementia patients. In Prevolnik Rupel (2003).
Mayo N, Goldber M, Kind P. Performance of the EuroQol EQ-5D in a Canadian population.
In Rabin et al (1998.)McLernon D, Dillon J, Donnan P. Health-state utilities in liver disease: a systematic review.
Medical Decision Making 2008; 28:582–92.
References 277
Meyer-Moock S, Moock J, Hessel F, Kohlmann T. Awareness, relevance and potential use of the
EQ-5D in German health care decision making processes. In Yfantopoulos (2010).
Mills T, Law S, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic
diseases: a systematic literature review. Drugs and Aging 2009; 26:933–50.
Moock J and Kohlmann T. Comparing the EQ-5D, SF-6D, HU12, QWB-SA and 15D: Which
measure can be recommended for use in the German system of medical rehabilitation?
In Pickard (2004).
Mulhern B, Tsuchiya A, Rowen D, Devlin N, Bansback N, Longworth L, Brazier J. Health state
valuation and mode of administration: head to head comparison of on-line and CAPI. Paper
presented at the 28th Scientific Plenary meeting of the EuroQol Group, Oxford, September
2011.
Murti B, Johnson J, Ohinmaa A, Sintonen H, Coons S. Comparison of Finnish- and US-based VAS
valuations of the EQ-5D. In Rabin et al (1998).Murti B, Johnson J, Ohinmaa A, Coons S. Comparison of Finnish and US-based VAS valuations of
the EQ-5D. In Greiner et al (1999).Nord E. The EuroQol Group: Papers written as part of the EuroQol enterprise, March 1992.
In Sintonen (1993a).
Nord E. The EuroQol Group: Systematic list of points made and lessons learned in the EuroQol
enterprise, March 1992. In Sintonen (1993b).
Nord E. The use of EuroQol values in QALY calculations. In Bj€ork (1992).
Nord E. The validity of a visual analogue scale in determining social weights for health scales.
International Journal of Health Planning and Management 1991; 6:234–242.
Nord E. (Ed.) EuroQol Plenary Meeting Oslo October 1996 Conference Porceedings. National
Institute of Public Health, Oslo, 1997a.
Nord E. Time trade-off scores in patients with chronic disease. Comparison with the York
hypothetical TTO tariff. In Nord (1997b).
Nord E, Badia X, Rue M, Sintonen H. Hypothetical evaluations of health states versus patients’
self-ratings. In Badia et al (1996).Nord E, Richardson J, Macarounas-Kirchmann K. Social evaluation of health care versus personal
evaluation of health states: evidence on the validity of four health-state scaling instruments
using Norwegian and Australian surveys. International Journal of Technology Assessment in
Health Care 1993; 9:463–478.
Norinder A and Krabbe P. On the relationship between trade-off and scaling techniques for the
valuation of health states. In Norinder et al (2002).Norinder A, Pedersen KM, Roos P. (Eds.) Proceedings of the 18th Plenary Meeting of the EuroQol
Group, Copenhagen, Denmark, September 2001. Swedish Institute for Health Economics,
2002.
Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource
allocation in children: a systematic methodological review. Value in Health 2011;14:1117–29.
Nuria L, Badia X, Montse R, Nuria P, Noelia B, Neus C. Use of the Spanish version of the EQ-5D
in different disease areas and population sub-groups. In Stavem (2005).
O’Hanlon M and Buxton M. (Eds.) EuroQol Plenary meeting London October 1994 Conference
Proceedings. Health Economics Research Group, Brunel University, 1995.
Ohinmaa A. Modelling valuations for EuroQol health states. Comparison of three tariff systems
based on the data collected in the University of York. In O’Hanlon and Buxton (1995).
Ohinmaa A and Sintonen H. Inconsistencies and modelling of the Finnish EuroQol (EQ-5D)
preference values. In Greiner et al (1999).Ohinmaa A and Sintonen H. The EQ-5D outcomes produced by different tariffs. In Nord (1997a).
Ohinmaa A, Eija H, Sintonen H. Modelling EuroQol values of the Finnish adult population.
In Badia (1996).
Oppe M and de Charro F. Estimating TTO-based value sets for EQ-5D using medians. In de
Pouvourville (2009).
278 References
Oppe M and van Hout B. The optimal hybrid: Experimental design and modelling of a combina-
tion of TTO and DCE. In Yfantopoulos (2010).
Oppe M, Oppe, de Charro F. Uncertainty in model applications from TTO studies. In Busschbach
et al (2007a).Oppe M, Szende A, de Charro F. Development of a methodology to gain insight on the use of
EQ-5D in different disease areas. In Stavem (2005).
Oppe M, van Hout B, de Charro F. A simulation study to explore the possibilities of using DCE as
a technique to elicit EQ-5D value sets. In Busschbach et al (2007b).Papaioannou D, Brazier J, Parry G How valid and responsive are generic health status measures,
such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value in Health
2011;14:907–20.
Parkin D and Devlin N. In defence of the visual analogue scale? In Prevolnik Rupel (2003).
Parkin D and Devlin N. Is there a case for using visual analogue scale valuations in cost-utility
analysis? Health Economics 2006; 15:653–664.
Parkin D, Devlin N, Sharma P. A deathless and VAS-free EQ-5D self-completion valuation
questionnaire. In Stavem (2005).
Parkin D, Rice A, Jacoby A. Use of the EQ VAS in a daily patient diary. In Badia et al (2000).Patrick D, Bush J, Chen M. Methods for measuring levels of well-being for a health status index.
Health Services Research 1973; 8:228–245.
Persson U, Glenngard A, Hjortsberg C. Estimating the willingness to pay for a QALY in Sweden:
a pilot study. In Scalone and Mantovani (2008).
Pickard AS. (Ed.) 21st Scientific Plenary Meeting of the EuroQol Group Discussion Papers,
September 2004, Chicago, USA. Center for Pharmacoeconomics Research, University of
Illinois, Chicago, 2004.
Pickard AS and Lin F. Is EQ-5D inferior in content to disease-specific utility measures?
In Yfantopoulos (2010).
Pickard AS, De Leon M, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the
standard EQ-5D to a 5-level version in cancer patients. In Badia (2007a).
Pickard AS, Kohlmann T, Cella D, Rosenbloom S, Bonsel G, Janssen M. A crosswalk for a 5 level
version of EQ-5D. Come together: use of IRT models to derive preference-based algorithms
for a 5 level version. In Badia (2007b).
Pickard AS, Wilke C, Hsiang-Wen L, Lloyd A. Impact of cancer on health related quality of life:
evidence using the EQ-5D. In Badia (2007c).
Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee T. Use of a preference-based measure of
health (EQ-5D) in COPD and asthma. Respiratory Medicine 2008;102:519–36.
Pickard AS, Wilke C, Jung E. Patel S, Stavem K, Lee T. Use of a preference-based measure of
health (EQ-5D) in COPD and asthma. In Busschbach (2007d).
Pickard AS, Wilke C, Lin H, Lloyd A. Health utilities using the EQ-5D in studies of cancer.
Pharmacoeconomics 2007e; 25:365–84.
Pinto J.L. Checking the interval properties of different scaling methods: application to some
EuroQol health states. In Badia et al (1996).PJB Publications. SCRIP’s 2000 pharmaceutical companies league tables. PJB Publications 2000.
Prevolnik Rupel V. (Ed.) 20th Plenary Meeting of the EuroQol Group Discussion Papers, Bled,
Slovenija, September, 2003. Republic of Slovenia Ministry of Health, 2003.
Prevolnik Rupel V and Rebolj M. The Slovenian VAS tariff based on valuations of EQ-5D health
states from the general population. In Cabases and Gaminde (2001).
Rabin R, Busschbach Jv, de Charro F, Essink-Bot M-L, Bonsel G. (Eds.) EuroQol Plenary
Meeting, Rotterdam, October 1997 Discussion Papers. Institute for Medical Technology
Assessment, 1998.
Rabin R, Herdman M, Fox-Rushby J, Badia X. Exploring the results of translating the EQ-5D into
11 European languages. In Brooks et el (2003).Ramos-Goni J, Errea M, Stolk E, Herdman M, Rivero-Arias D, Cabases J. Discrete choice (DC)
models: anchor in death or in time trade-off (TTO) values? Spanish pilot study of the EQ-5D
valuation project. Paper presented at the 28th Scientific Plenary meeting of the EuroQol Group,
Oxford, September 2011.
References 279
Rand-Hendriksen K, Augestad L, Kristiansen I, Stavem K. Comparison of hypothetical and
experienced EQ-5D valuation: relative weights of the 5 dimensions. In Yfantopoulos (2010).
Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burstr€om K, Cavrini G, Devlin N, Egmar A-C,
Gusi N, Herdman M, Jelsma J, Kind P, Olivares P, Scalone L, Greiner W. Feasibility,
reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life
Research 2010; 19:887–97.
Rebolj M and Prevolnik Rupel V. Socioeconomic inequalities in health of the Slovenian popula-
tion measured by the EQ-5D instrument. In Norinder et al (2002).Rebolj M, Oppe S, Oppe M, Rabin R, Szende A, Cleemput I, de Charro F, Williams A. What light
does EQ-5D shed on international differences in self-reported health problems by age, sex and
educational level? In Kind and Macran (2002a).
Roset M, Badia X, Herdman M, Kind P. A comparison of English and Spanish general population
TTO values for EQ-5D health states: preliminary results. In Greiner et al (1999).Roset M, Badia X, Benavides A, Herdman M. The validity of the EQ-5D in children with asthma.
In Badia et al (2000).Rosser R and Kind P. A scale of valuations of states of illness: is there a social consensus?
International Journal of Epidemiology 1978; 7:347–358.
Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Gaeta L, Del Prete A, Magini G, Baldan A,
Mantovani L. Comparing the standard EQ-5D-3L versus 5L version for the assessment of
health of patients with liver diseases. In Yfantopoulos (2010).
Scalone L, Cristiani M, Cortesi P, Morsanutto A, Meneghini M, Mantovani L. Assessment
of preferences toward different health states traded off with life duration and death: further
application and investigation of the performance of Discrete Choice Analysis. In de
Pouvourville (2009).
Scalone L and Mantovani L. (Eds.) 25th Scientific Plenary Meeting of the EuroQol Group
Proceedings, Baveno, Italy, September 2008. EuroQol Group Executive Office, 2008.
Secnik K, Matza L, Mannix S, Sallee F. Use of the EQ-5D proxy version in a sample of parents
who have children diagnosed with attention deficit/ hyperactivity disorder (ADHD).
In Prevolnik Rupel (2003).
Secnik, K, Matza, L, Mannix, S.The proxy EQ-5D as a quality of life measure in UK children with
attention deficit/ hyperactivity disorder. In Pickard (2004).
Selai C. The use of the EuroQol descriptive (pages 2 and 3) with patients at the Institute of
Neurology, London. In O’Hanlon and Buxton (1995).
Selai C. Four levels and a funeral: preliminary testing of a four-level EuroQol descriptive
classification system. In Badia et al (1996).Selai C. The problem of inconsistencies in elicited EQ values: discussion paper. In Badia et al
(2000).
Selai C. Testing the EuroQol 3-level and 4-level descriptive classification systems. In Nord
(1997a).
Selai C, Gaminde I, Herdman M, Johnson J, Rabin R. EQ-5D: modes of administration. In Brooks
et al (2003).Selai C and Rosser R. Eliciting EuroQol descriptive data and utility scale values from seriously ill
in-patients: the pharmaco-economic relevance. In Busschbach et al (1994).Shah K, Lloyd A, Devlin N. Understanding participants’ responses to valuation tasks: implications
for EQ-5D-5L valuation studies. Paper presented at the 28th Scientific Plenary Meeting of the
EuroQol Group, Oxford, September 2011.
Shaw J, Johnson J, Iannacchione V, Coons S. US valuation of the EQ-5D health states: methods,
sampling, and preliminary analyses. In Prevolnik Rupel (2003).
Shaw J, Luo X, Pickard AS, Walton S. Efficiency of estimation with the the US popula-
tion median-based EQ-5D Index: findings from the Medical Expenditure Panel Survey.
In Yfantopoulos (2010a).
Shaw J, Zhan L, Oppe M. Evaluation of conditional median models of EQ-5D health states
preferences using data collected in four countries. In Yfantopoulos (2010b).
280 References
Sintonen H. An approach to measuring and valuing health states. Social Science and Medicine
1981; 15c: 55–65.
Sintonen H. (Ed.) EuroQol Conference Proceedings Helsinki October 1992. Department of Social
Sciences, University of Kuopio, 1993.
Sintonen H, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Greiner W, Krabbe P,
Ohinmaa A, Roset M, de Charro F. Comparison of EQ-5D VAS valuations: analysis of
background variables. In Brooks et al (2003).Sintonen H. EuroQol vs. 15D: a comparison of two health-related quality of life measures.
In O’Hanlon and Buxton (1995).
Solem C, Gu N, Pickard AS. Predicting VAS scores by EQ-5D Items and presence of disease:
a bolt-on feasibility study. Paper presented at the 28th Scientific Plenary meeting of the
EuroQol Group, Oxford, September 2011.
Stavem K. (Ed.) 22nd Plenary Meeting of the EuroQol Group Discussion Papers, Oslo, Norway,
September 2005. Helse-Øst Health Services Research Centre, Lørenskog, 2005.
Steinbrocker O, Traeger C, Battman R. Therapeutic criteria in rheumatoid arthritis. Journal of the
American Medical Association 1949: 140:653–662.
Stolk E, Krabbe P, Busschbach J. Using the Internet to collect EQ-5D norm scores: a valid
alternative? In Busschbach et al (2007).Stolk E, Oppe M, Scalone L, Krabbe P. Discrete choice modelling for the quantification of health
states: the case of the EQ-5D. In Scalone and Mantovani (2008).
Stolk E and van Busschbach Jv. The performance of EuroQol in children. In Greiner et al (1999).Stouthard M and Essink-Bot M-L. EuroQol 1991–The Rotterdam Survey–Results. In Bj€ork
(1992).
Szanto Z and Susansky E. Quality of life and social inequalities in the middle aged Hungarian
population: a population survey utilization of the EQ-5D. In Prevolnik Rupel (2003).
Szende A and Williams A (Eds.) Measuring Self-Reported Population Health: An International
Perspective based on EQ-5D. SpringMed Publishing 2004.
Szende A. The (potential) role of the EQ-5D in the international comparison of socioeconomic
inequalities in health status. In Kind and Macran (2002a).
Szende A, OppeM, Devlin N. (Eds.) EQ-5D Value Sets: Inventory, Comparative Review and User
Guide. Springer 2007.
The EuroQol Group. EuroQol–A new facility for the measurement of health-related quality of life.
Health Policy 1990; 16:199–208.
The EuroQol Group. Not a quick fix. Health Service Journal 1991;101(5279):29.
Thompson S, Holtzer-Goor K, Schaafsma R, Uyl-de Groot C. Use of a 5-level EQ-5D instrument
without additional labels in patients with chronic lymphocytic leukaemia. In Badia (2007).
Tilling C, Devlin N, Tsuchiya A, Buckingham K. Time Trade Off valuation of EQ-5D states worse
than dead: a feasibility study. In Scalone and Mantovani (2008).
Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of
health-related quality of life in visual disorders. Value in Health 2012; 15:118–27.
Tsuchiya A, Brazier J, McColl E, Parkin D. A condition-specific instrument, a generic instrument,
and a preference-based generic instrument. In Norinder et al (2002a).Tsuchiya A, Brazier J, Roberts J. Comparison of valuation methods used to generate the EQ-5D
and the SF-6D value sets in the UK. In Kind and Macran (2002b).
Tsuchiya A, Mulhern B, Buckingham K, Devlin N. Testing lead time TTO issues in an online
environment. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group,
Oxford, September 2011.
van Agt H and Bonsel G. The number of levels in the descriptive system. In Busschbach et al(1994).
van Dalen H, Williams A, Gudex C. Lay people’s evaluation of health: are there variations
between different subgroups? Journal of Epidemiology and Community Health 1994;
48:248–253.
van Hout B and McDonnell J. Estimating a parametric relation between health description and
health valuation using the EuroQol. In Bj€ork (1992).
References 281
Vasquez-Polo F, Negrin M, Badia X, Roset M. A Bayesian model of cost-effectiveness with
EQ-5D data. In Kind and Macran (2002a).
Weijnen T, Nieuwenhuizen M, Ohinmaa A, de Charro F. Construction of the EQ-net VAS and
TTO databases. In Brooks et al (2003).Wilke C, Karabastos G, Pickard AS. Application of Kernel regression item response theory for
evaluation of EQ-5D 3L and 5L systems. In Scalone and Mantovani (2008).
Wilke C, Karabatsos G, Pickard AS. Comparison of patient and proxy health related quality of life
ratings using parametric and nonparametric item response theory approaches. In de
Pouvourville (2009).
Wille N, Badia X, Bonsel G, Burstr€om K, Cavrini G, Devlin N, Egmar A-C, Greiner W, Gusi N,
Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y:
a child-friendly version of the EQ-5D. Quality of Life Research 2010; 19:887–97.
Wille N, Hale S, Ravens-Sieberer U, Kohlmann T, Greiner W. Feasibility and preliminary validity
of a German EQ-5D childrens version. In Stavem (2005).
Wille N, Ravens-Sieberer U. and the child-friendly task force on behalf of the EuroQol Group.
Establishing definitions of the concepts included in CF-EQ-5D: A revision of the “Definition of
EQ-5D concepts” for adults. In Badia (2007).
Williams A. Foreword. In Brooks et al (2003).Wittrup-Jensen K, Lauridsen J, Gudex C, Brooks R, Pedersen KM. Estimating Danish EQ-5D
tariffs using the time trade-off (TTO) and visual analogue scale (VAS) methods. In Norinder
et al (2002).Wittrup-Jensen K, Lauridsen J, Pedersen KM. Valuation of EQ-5D health states using the person
trade-off method. In Badia (2007).
Yang Y, Brazier J, Tsuchiya A. The effect of adding a ‘sleep’ dimension to EQ-5D. Paper given at
the Health Economists’ Study Group Meeting, January 2008.
Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. Testing the impact of three
add-ons to the EQ-5D: a pilot study. Paper presented at the 28th Scientific Plenary Meeting of
the EuroQol Group, Oxford, September 2011.
Yfantopoulos J. Quality of life measurement and health production in Greece. In Greiner et al(1999).
Yfantopoulos J and Sintonen H. Comparison of the properties of the EQ-5D with the15D in
Finland and Greece. In Norinder et al (2002).Yfantopoulos J, Papagianopoulou V, Rachiotis G, Bechrakis P. Socio-economic inequalities in
health status and HRQOL among manual and non-manual workers in Greece. In Prevolnik
Rupel (2003).
Yfantopoulos J. (Ed.) 27th Scientific Plenary Meeting of the EuroQol Group Proceedings, Athens,
Greece, September, 2010. EuroQol Group Executive Office, 2010.
Yu S, Shaw J, Chen S, Iannacchione V, Johnson J, Coons S. A median model of US EQ-5D health
state preferences. In Busschbach et al (2007).
282 References
Index
AAgency for Healthcare and Quality
(AHRQ), 102
American Rheumatism Association, 1
Application papers
Barcelona Plenary Meeting (1995), 132
Brunel PlenaryMeeting (1994), 132
child-centred papers, 135
clinical areas, 142
Copenhagen meeting, 2001, 134
CSPTF activities, 140
disease areas programme, 136, 138
EQ-net book, 136
EuroQol Group, reviews, 141
Hannover Scientific meeting, 1998, 132, 134
3L and 5L versions, 139
Oslo meeting, 136–137
Pamplona Scientific Plenary meeting,
2000, 134
programmes and settings, 142, 143
registrations, 142–144
Rotterdam Plenary Meeting (1993), 131
Sitges Scientific Plenary meeting, 199, 134
31st meeting, Paris (September 2009), 140
task force’s activities, 137
Attention deficit hyperactive disorder
(ADHD), 205
BBiomed EQ-net project
annual activity report, 153
EQ-5D, 154
exploitation plans, 153
project milestones, 152
TVA, 152
CChild-Friendly TF (CFTF), 204
Common Core Group terminology, 16
Condition specific task force (CSPTF)
bolt-ons, 233
DimExs, 234
non-EQ members, 234–235
remarks, 236
Contract research organisations (CROs), 163
DDevelopment Electronic Valuation
Technology (DEVT), 118
Digital task force (DTF)
action points, 226
approval procedures, 226
ClinPhone contract, 225
Clinphone plus reaction, 224
EEP, 223
invivodata, 226
necessary changes, 225
nomenclature, 225
computer interrogation, 222–223
VAS, 225–226
Discrete choice experiments (DCE), 80, 103
EEQ-5D descriptive system
Barcelona Plenary Meeting 1995, 44
Barcelona Plenary Meeting September
2006, 56
Baveno Plenary Meeting September 2008,
57–58
Brunel Plenary Meeting 1994, 43
R. Brooks, The EuroQol Group after 25 years, DOI 10.1007/978-94-007-5158-3,# Springer Science+Business Media Dordrecht 2013
283
EQ-5D descriptive system (cont.)Chicago Plenary Meeting 2004, 49
Copenhagen Plenary Meeting September
2001, 48
development
from 2009, 63–64
dimension selection, 38–39
energy/vitality, 41
EuroQol classification, 42
family and leisure activities, 41
health states 5D version, 40
language, 39
levels, 39
objectives, 38
requirements, 38
early meetings, attendance, 261
Eighth Executive Committee Meeting May
2004, 49
Eleventh Executive Committee Meeting
February 2005
EQ-5D product development, 50
Funding 2005, proposals, 51
labelling, 51
standardised EQ-5D, proposals
to change, 51
EQ-5D-3L, 249–250
EQ-5D-5L, 251–252
Final Report of the 5L/Labelling Task
Force to the Executive Committee,
62
First EQ-5D Increased Level Task Force
Meeting November 2005, 53–54
Fourteenth Executive Committee Meeting
February 2006, 54
Fourth Labelling Sub-task Force Meeting
September 2006, 56
Hannover Plenary Meeting 1998, 46, 47
Helsinki Plenary Meeting 1992, 42–43
Labelling Sub-task Force Consensus Report
dimensions, 59
levels and labels, 59–61
progress and process-October 2008,
58–59
Liaison Officers Meeting April 1993, 43
Lund Plenary Meeting 1991, 42
Netherlands Plenary Meeting September
2007, 56–57
Oslo Plenary Meeting 1996, 44–45
Oslo Plenary Meeting 2005, 51–52
Rotterdam Plenary Meeting 1993, 43
Rotterdam Plenary Meeting 1997, 45
Second Increased Level Task Force
Meeting March 2006, 54–55
Sitges Plenary Meeting 1999, 46
Sixteenth Executive Committee Meeting
June 2006, 55–56
Subsequent Meetings of the Task Force, 56
Tenth Executive Committee Meeting
Chicago September 2004
EQ-5D 5-Level Version, 49–50
standardised EQ-5D, proposals to
change, 50
Third Labelling Sub-task Force Meeting
May 2006, 55
Twelfth Executive Committee Meeting
Oslo September 2005, 52
Twenty-Fourth Executive Committee
Meeting April 2008, 57
Twenty-Second Executive Committee
Meeting December 2007, 57
Twenty-Seventh Executive Committee
Meeting November 2008, 61–62
York Plenary Meeting 2002, 48–49
EQ-net project
cognitive/conceptual problems, 74
EQ-5D concepts, 72
European languages, 73
evident variations, 72
further research, 72–73
health outcomes assessment, 74
interview process, 73
language versions, 73
quality control, 73
EuroQol electronic programme (EEP), 223
EuroQol Group
current Group membership, 259
external environment, 247–248
1990 Health Policy article, members, 263
membership changes, 265–266
strategy, 246–247
strengths, 245–246
EuroQol instrument, early meetings
EuroQolus exercise, 32–34
Fifth meeting, July 1989, 22
being dead treatment, 24
commentary, 25
data exchange, 24
data report, 23
descriptors presentation, 23–24
development programme, publications
and membership, 24–25
EuroQol measure, 22–23
scaling method, validity and response
rates, 23
socio-demographic data, 24
First meeting, May 1987, 14–16
284 Index
Fourth meeting, July 1988
extended core, 18
health states, 21
protocol, core data, 20–21
restricted core, 18
selected core states, 22
thermometer, 19
valuation task, 18
medical and related interventions, 13
multidisciplinary collaboration, 14
reductionist approach, 14
Second meeting, October 1987, 16, 17
Seventh meeting, September 1990
data handling arrangements, 30
experiments, 30
finance, 32
membership, 31
objectives, 28
organisational matters, 31
presentation, 29
publications, 30
revised descriptors, 28–29
Sixth meeting, January 1990
being dead treatment, 26
descriptors, 26
future meetings, 27–28
multi-stage vs. composite single stage
valuations, 26
objectives, 25
organisational and procedural
matters, 27
publications, 27
thermometer, 27
Third meeting, January 1988, 16–18
EuroQol organisation and administration
Barcelona Plenary Meeting (1995),
148–151
Biomed EQ-net project
annual activity report, 153
EQ-5D, 154
exploitation plans, 153
project milestones, 152
TVA, 152
Brunel Plenary Meeting (1994), 148–149
copyright and legal issues
EQ-5D-3L, 163
EQ-5D language, 162–163
EQ-5D translations, 162
Group products, 163–164
recommendations, 162
data archiving, 193–195
Executive Committee
by-laws and rules, 156, 158
Dutch Trade Register, 158–159
election procedures, 156, 157
legal advice, 156
membership, 155
research grant applications, 160–161
role and functioning, 155
task force managers, 159
finance
Barcelona Association Meeting,
1995, 165
Bled Association Meeting, 2003, 167
Brunel Plenary Meeting, 1994, 165
Chicago Association Meeting,
2004, 167
Copenhagen Association Meeting,
200, 166–167
EQ funded projects, 168–169
Hannover Association Meeting,
1998, 165
large scale users, 170
Liaison Officers Meeting, April 1993,
164
5L valuation, 170
Oslo Association Meeting, 1996, 165
Pamplona Association Meeting,
2000, 166
Paris Association Meeting, September
2009, 170
Rotterdam Plenary meeting, 1993, 164
Scientific Plenary meeting, 176
Sitges Association Meeting, 1999,
165–166
soaring activities, 171
usage groups, 169–170
York Association Meeting, 2002, 167
formative years 1987–1991, 145–146
Helsinki (1992), Plenary Meeting,
146–147
Lund (1991), Plenary Meeting, 146–147
membership
Barcelona Plenary Meeting (1995),
177–178
benefits, 179–180
Copenhagen Board Meeting (2001),
179–180
EuroQol group membership, 178, 179
invitation, 185
MRG feedback, 183–184
option 1, 182
Pamplona Association Meeting (2000),
178
43rd meeting, Oxford (September
2011), 184
Index 285
review report (January 2010), 181
17th meeting, Barcelona (September
2006), 181
10th meeting, Chicago (September
2004), 180
York Association Meeting (2002), 178
Plenary meeting arrangements
Brunel Association Meeting, 1994, 171
Copenhagen Association Meeting,
2001, 172
scientific meetings, 172
York Association Meeting, 2002,
172–173
publications, 192–193
publicity, 190–192
Rotterdam Plenary Meeting (1993), 148
user interaction
EQ-5D-3L descriptive system, 189
EQ-5D Use, Canada, 190
EQ VAS, 189–190
refining and testing, 188
31st meeting, Paris (September 2009),
188
26th meeting, Baveno (September
2008), 188
UK developments, 187
HHealth Economists’ Study Group (HESG), 2
Health-related quality of life (HRQoL)
Business Management, 4
decision-making, 3
disease-specific measures, 1
EuroQol family
copyright policy, 8
Group’s activities, 6
injury review, 10
membership rules, 11
modelling and valuation, 7
Plenary Meetings, 6
publications, 11
scientific contributions, 9
socio-economic aspects, 9
Translation Committee, 7
Xhosa language version, 10
Youth Task Force, 8
language versions, instrument, 3
narrative, 4–5
preference-based valuations, 2
pre-history, 2–3
sources and references, 5
IInternational Society for Pharmacoeconomics
and Outcomes Research (ISPOR), 5
LLanguage versions
EQ-5D-3L, 253–254
EQ-5D-5L, 255–256
EQ-5D-Y, 257
Liaison Panel, 31
Likert scaling, 80
MMagnitude estimation, 80
Measurement andValuation ofHealth (MVH), 7
Membership review group (MRG), 181
NNational Institute for Clinical Excellence
(NICE), 101
Nottingham Health Profile (NHP), 15
Novo Nordisk translations, 69–70
PPaired comparisons, 80
Patient reported outcome measures (PROMs),
170
Person trade-off (PTO), 80
Population health task force (PHTF)
First Meeting November 2007, 237–239
Fourth Meeting Athens September 2010,
243–244
research areas, 243
Second Meeting Baveno September 2008,
239
suggestions, 243–244
Third Meeting Paris September 2009,
240–242
Product development strategy
age ranges, 212–213
Baveno September 2008, 227
Cheerleader project applications, 198
dimensions, 214–215
electronic versions, 231–232
EQ-5D 5-level field testing, 235–236
Executive Committee
12th Meeting Oslo, September 2005,
201
286 Index
17th Meeting Barcelona, September
2006, 202
21st Meeting The Hague, September
2007, 203
26th Meeting Baveno, September 2008,
203–204
5L, expansion, 216
memorandum
EuroQol instrument, 199
potential EQ-5D products, 200
research priorities, 202
papers and publications
adult vs. child versions, 220
EQ-5D-Y, 221–222
Nora Wille and Ulrike Ravens-Sieberer,
220–221
proxy versions
adult proxy guidelines, 210–211
EQ-5D-Y valuation, 212
valuations
EQ-5D-Y version, 219
Luciana’s document, 217
3L Youth version, 218
Nancy Devlin, 217
VAS, 214
PROMs. See Patient reported outcome
measures (PROMs)
QQuality-adjusted life years (QALYs), 3
Quality of Well-being (QWB), 2, 15
SSickness Impact Profile (SIP), 15
Standard gamble (SG), 80
TTime-trade off (TTO), 80, 81
Translation issues
Barcelona Plenary Meeting 1995, 67–68
Brunel Plenary Meeting 1994, 66–67
EQ-net project
Barcelona Plenary Meeting 2006, 75
cognitive/conceptual problems, 74
EQ-5D concepts, 72
European languages, 73
evident variations, 72
further research, 72–73
The Hague, The Netherlands September
2007, 75–77
health outcomes assessment, 74
interview process, 73
language versions, 73
quality control, 73
guidelines, 67
Hannover Plenary Meeting 1998, 71
Oslo Plenary Meeting 1996
Czech translation report, 70
decisions and action, 68–69
Scientific Meeting, 69–70
Rotterdam Plenary Meeting 1997, 70
Sitges Plenary Meeting 1999, 71
TTO. See Time-trade off (TTO)
VValuation, EQ-5D
Association Meetings, 101–102
Athens Plenary Meeting 2010, 121
Barcelona Plenary Meeting 1995, 87–88
Baveno Italy Plenary Meeting 2008,
110, 111
biomed EQ-Net Project, 1998–2001
EQ-5D TTO values, 95–96
EQ-5D VAS valuations, 92–93
European EQ-5D VAS valuation set,
93–95
VAS and TTO databases, 91–92
Brunel Plenary Meeting 1994, 84–85
4C Pilot Study Analysis Team Meeting
May 2011, 124–125
DCE Meeting March 2007, 106–107
early years, 1987‐1990, 79–81Eighth VTF Meeting May 2009, 114–115
Eleventh VTF Meeting February 2010,
118–119
Executive Committee, 101–103
Fifteenth VTFMeeting December 2010, 123
Fifth VTF Meeting May 2007, 108–109
First EQ-5D Valuation Task Force Meeting
June 2006
position papers, 104
prioritisation, 104–105
Fortieth Executive Committee Meeting
March 2011, 124
Forty-Fourth Executive Committee
Meeting December 2011, 128–129
Forty-Second Executive Committee
Meeting June 2011, 125
Fourteenth VTF Meeting Athens
September 2010, 121
Fourth VTF Meeting March 2007, 107–108
Hannover Plenary Meeting 1998, 89
Index 287
Valuation (cont.)Helsinki Plenary Meeting 1992, 82–83
Lund Plenary Meeting 1991, 81–82
3L valuation protocol, 112–113
The Netherlands Plenary Meeting
September 2007, 109
Ninth VTF Meeting Paris September
2009, 116
Oslo Plenary Meeting 1996, 88
Oxford Plenary Meeting September
2011, 127
Pamplona Plenary Meeting 2000, 90
Paris Plenary Meeting 2009, 116
Plenary Meetings 2001–2007
economics papers, 100
HRQoL instruments, 99
5-level approach, 99–100
modelling, 99
TTO, 98
valuation-related papers, 100–101
VAS, 96–98
publication plan multi-country valuation
study, 126
Rotterdam Plenary Meeting 1993, 83–84
Rotterdam Plenary Meeting 1997, 89
Second VTF Meeting November 2006,
105–106
Seventh VTF Meeting February 2009, 114
Sitges Plenary Meeting 1999, 90
Sixteenth VTF Meeting March 2011, 123
Sixth VTF Meeting Baveno September
2008, 110–111
State of Play Paper 1996
alternative scaling approaches, 86
health states, number of, 85–86
modelling, 86–87
valuation task, 85
Tenth VTF Meeting October 2009, 117
Thirteenth VTF Meeting May 2010, 120
Thirtieth Board Meeting November
2009, 117
Thirty-Eighth Executive Committee
Meeting October 2010, 122
Thirty-First Executive Committee Meeting
Paris September 2009, 115
Thirty-Ninth Executive Committee
Meeting November 2010, 123
Thirty-Seventh Executive Committee
Meeting September 2010 Athens,
122
Thirty-Sixth Executive Committee Meeting
June 2010, 119–120
Twelfth VTF Meeting 26 April 2010, 119
Twenty-First Board Meeting October 2006,
105
Twenty-Ninth Executive Committee
Meeting July 2007, 109
Twenty-Ninth Executive Committee
Meeting May 2009, 115
VTF Meeting June 2011, 125
Version Management Group (VMG), 63, 77
Visual analogue scale (VAS), 80, 81
YYouth task force
ADHD, 205–206
CFTF, 204
child-friendly, 205
EQ-5D, 206
EQ-5D-Y, 204–205
The Hague, September 2007, 209
instrument, 207
international English version, 209
Ravens-Sieberer material, 208
Sitges, 1999, 205
288 Index